Heidar Sharafi

24.9k total citations
89 papers, 818 citations indexed

About

Heidar Sharafi is a scholar working on Epidemiology, Hepatology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Heidar Sharafi has authored 89 papers receiving a total of 818 indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Epidemiology, 69 papers in Hepatology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Heidar Sharafi's work include Hepatitis C virus research (66 papers), Hepatitis B Virus Studies (64 papers) and Liver Disease Diagnosis and Treatment (50 papers). Heidar Sharafi is often cited by papers focused on Hepatitis C virus research (66 papers), Hepatitis B Virus Studies (64 papers) and Liver Disease Diagnosis and Treatment (50 papers). Heidar Sharafi collaborates with scholars based in Iran, Canada and United States. Heidar Sharafi's co-authors include Seyed Moayed Alavian, Bita Behnava, Maryam Keshvari, Mohammad Gholami Fesharaki, Ghobad Moradi, Amjad Mohamadi Bolbanabad, Farzin Sadeghi, Yousef Moradi, Hamidreza Karimi‐Sari and Hossein Keyvani and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Microbiology and Addiction.

In The Last Decade

Heidar Sharafi

86 papers receiving 810 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heidar Sharafi Iran	17	622	605	97	59	45	89	818
Arício Treitinger Brazil	15	338 0.5×	229 0.4×	136 1.4×	27 0.5×	26 0.6×	32	532
Van Thi Thuy Nguyen Vietnam	11	433 0.7×	317 0.5×	154 1.6×	64 1.1×	13 0.3×	29	603
Vu Q. Binh Germany	13	264 0.4×	210 0.3×	121 1.2×	34 0.6×	82 1.8×	17	516
Kung‐Chia Young Taiwan	10	290 0.5×	291 0.5×	61 0.6×	153 2.6×	31 0.7×	16	630
Hie‐Won Hann United States	15	1.7k 2.8×	1.7k 2.8×	258 2.7×	58 1.0×	8 0.2×	33	1.9k
R. Crabbé Switzerland	10	345 0.6×	421 0.7×	98 1.0×	241 4.1×	15 0.3×	28	616
Kei Fujiwara Japan	17	721 1.2×	717 1.2×	136 1.4×	186 3.2×	14 0.3×	66	978
Christine Lee United States	13	370 0.6×	220 0.4×	111 1.1×	115 1.9×	7 0.2×	36	676
Torkil Moestrup Sweden	14	351 0.6×	349 0.6×	88 0.9×	24 0.4×	13 0.3×	18	513
Etsuko Iio Japan	17	626 1.0×	584 1.0×	144 1.5×	190 3.2×	11 0.2×	52	842

Countries citing papers authored by Heidar Sharafi

Since Specialization

Citations

This map shows the geographic impact of Heidar Sharafi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidar Sharafi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidar Sharafi more than expected).

Fields of papers citing papers by Heidar Sharafi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidar Sharafi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidar Sharafi. The network helps show where Heidar Sharafi may publish in the future.

Co-authorship network of co-authors of Heidar Sharafi

This figure shows the co-authorship network connecting the top 25 collaborators of Heidar Sharafi. A scholar is included among the top collaborators of Heidar Sharafi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidar Sharafi. Heidar Sharafi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharafi, Heidar, et al.. (2026). A call for action: Closing the evidence gap in management of stimulant‐induced psychosis. Addiction.

Tavakoli, Fatemeh, et al.. (2024). Self-reported lifetime Hepatitis B virus testing, and vaccination uptake among people who inject drugs in Iran: a nationwide study in 2020. BMC Public Health. 24(1). 3156–3156.

Sharafi, Heidar, et al.. (2024). Is Naltrexone Effective and Safe for Treating Amphetamine-Type Stimulant Use Disorder? A Systematic Review and Meta-analysis. Journal of Addiction Medicine. 19(3). 322–330.

Sharafi, Heidar, et al.. (2024). Efficacy and Safety of Modafinil for Treatment of Amphetamine-Type Stimulant Use Disorder: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials: Efficacité et innocuité du modafinil pour le traitement des troubles liés à l'usage de stimulants de type amphétamine : revue systématique et méta-analyse d'essais randomisés contrôlés par placebo. The Canadian Journal of Psychiatry. 69(11). 793–805. 1 indexed citations

Sharafi, Heidar, Sarah Drouin, Suzanne Brissette, et al.. (2023). Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA. The Canadian Journal of Psychiatry. 69(4). 252–263. 1 indexed citations

Sharafi, Heidar, Sarah Drouin, Stephanie Coronado‐Montoya, et al.. (2023). Prescription psychostimulants for the treatment of amphetamine‐type stimulant use disorder: A systematic review and meta‐analysis of randomized placebo‐controlled trials. Addiction. 119(2). 211–224. 9 indexed citations

Sharafi, Heidar, Arash Bahremand, Sarah Drouin, et al.. (2023). Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug and Alcohol Dependence. 253. 111018–111018. 3 indexed citations

Sharifi, Hamid, et al.. (2023). Trends in the Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infections in Iranian Patients with Hereditary Bleeding Disorders. Pathogens. 12(4). 555–555. 2 indexed citations

Mirzazadeh, Ali, Armita Shahesmaeili, Heidar Sharafi, et al.. (2022). An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. International Journal of Drug Policy. 102. 103580–103580. 8 indexed citations

10.

Mohammadi, Hamed, Seyed Moayed Alavian, & Heidar Sharafi. (2022). Association of single nucleotide polymorphisms in immune-related genes with spontaneous HBsAg seroconversion: A systematic review and meta-analysis. International Immunopharmacology. 110. 108982–108982. 1 indexed citations

11.

Shokoohi, Mostafa, et al.. (2021). COVID-19 Among Patients With Hepatitis B or Hepatitis C: A Systematic Review. Hepatitis Monthly. 20(11). 5 indexed citations

12.

Sharafi, Heidar, et al.. (2021). Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. Virology Journal. 18(1). 199–199. 6 indexed citations

13.

Hashempour, Tayebeh, et al.. (2021). First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterology. 21(1). 443–443. 11 indexed citations

14.

Sharafi, Heidar, Saman Ghalamkari, Alireza Hassanshahi, & Seyed Moayed Alavian. (2019). Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microbial Drug Resistance. 25(7). 1072–1079. 1 indexed citations

15.

Sharafi, Heidar, et al.. (2018). Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review. Clinical Chemistry and Laboratory Medicine (CCLM). 57(5). 577–610. 26 indexed citations

16.

Alavian, Seyed Moayed, et al.. (2015). High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study. Pediatric Hematology and Oncology. 32(6). 399–405. 4 indexed citations

17.

Sali, Shahnaz, et al.. (2015). Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?. Diagnostic Microbiology and Infectious Disease. 82(2). 114–119. 6 indexed citations

18.

Sharafi, Heidar, et al.. (2014). Effect of seasonal changes on the prevalence of uropathogens in 2010-2011and determination of antibiotic resistance pattern of Escherichia coli in three neighbor cities; Shiraz, Marvdasht and Saadat-Shahr. SHILAP Revista de lepidopterología. 1 indexed citations

19.

Bahoush, Gholamreza, et al.. (2014). Association of -24CT, 1249GA, and 3972CT ABCC2 Gene Polymorphisms with Methotrexate Serum Levels and Toxic Side Effects in Children with Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology. 31(2). 169–177. 23 indexed citations

20.

Keshvari, Maryam, et al.. (2014). Interferon Alpha-2b Therapy in Chronic Hepatitis Delta. Hepatitis Monthly. 14(3). e15729–e15729. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact